fool.com · 2 jul

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug delivery system that gives it a deeper moat.

seekingalpha.com · 25 jun

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders Transcript

businesswire.com · 25 jun

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo's analytics AI platform, across key enterprise functions at Alnylam. Built on the Healthcare Map®, the industry's most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyon.

zacks.com · 22 jun

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.

forbes.com · 17 jun

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

zacks.com · 16 jun

Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com · 12 jun

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?

Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.

businesswire.com · 12 jun

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company's pipeline programs, as well as medical thought leaders who will provide their perspectives on unmet clinical needs. Each event will b.